Naringenin Supplementation in Bone Fracture Patients

Fractures of the lower extremities represent a significant proportion of injuries sustained by polytrauma patients, with a notable association with prolonged hospitalization, chronic disability, and impaired physical functioning. The occurrence of surgical site infections (SSI) represents a significant threat to the efficacy of osteosynthesis procedures. As with other traumas and surgical procedures, the secretion of inflammatory mediators is markedly elevated in this cohort of patients following surgery. Naringenin is one of the most prevalent flavonoids, occurring naturally in grapefruit and other citrus fruits. In vitro studies have demonstrated that naringenin may stimulate the release of osteogenic cytokines and suppress the production of pro-inflammatory factors, which can result in a reduction in bone resorption. Based on these findings, naringenin may prove an effective agent for accelerating the rate of fusion and controlling inflammation. Furthermore, it may enhance quality of life and augment functional activity.

NCT Number	NCT06612762
Lead Sponsor	Shahid Beheshti University of Medical Sciences
Conditions	Bone Fractures
Enrollment	70 participants
Start Date	2024-11-03
Primary Completion	2026-10-19 (estimated)
Study Completion	2026-11-02 (estimated)
Updated on ClinicalTrials.gov	2026-07-30